Publication showing Ivermectin of no use treating COVID

Another science-based report that the use of ivermectin is not indicated in treating mild to moderate covid infections. When will the non-scientists start believing in science?

IMPORTANCE The effectiveness of ivermectin to shorten symptom duration or prevent
hospitalization among outpatients in the US with mild to moderate symptomatic
COVID-19 is unknown.
OBJECTIVE To evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with
placebo for the treatment of early mild to moderate COVID-19.
DESIGN, SETTING, AND PARTICIPANTS ACTIV-6, an ongoing, decentralized, double-blind,
randomized, placebo-controlled platform trial, was designed to evaluate repurposed
therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30
years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute
infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022,
with follow-up data through May 31, 2022, at 93 sites in the US.
INTERVENTIONS Participants were randomized to receive ivermectin, 400 μg/kg (n = 817),
daily for 3 days or placebo (n = 774).
MAIN OUTCOMES AND MEASURES Time to sustained recovery, defined as at least 3
consecutive days without symptoms. There were 7 secondary outcomes, including
a composite of hospitalization or death by day 28.
RESULTS Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932
women [58.6%]; 753 [47.3%] reported receiving at least 2 doses of a SARS-CoV-2 vaccine),
1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07
(95%credible interval [CrI], 0.96-1.17; posterior P value [HR >1] = .91). The median time to
recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the
placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the
placebo group (1.2%vs 1.2%; HR, 1.1 [95%CrI, 0.4-2.6]). The most common serious adverse
events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous
thromboembolism (ivermectin [n = 1]; placebo [n = 5]).
CONCLUSIONS AND RELEVANCE Among outpatients with mild to moderate COVID-19,
treatment with ivermectin, compared with placebo, did not significantly improve time to
recovery. These findings do not support the use of ivermectin in patients with mild
to moderate COVID-19.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04885530

TexChik · F

Tell that to the tens of thousands in India that were saved by Ivermectin in combination with quercetin, Vit D, Zinc, and Vit A. People stopped dying and became symptom and virus free in 5-7 days. My neighbor went over there and volunteered . It worked. Big pharma wants everyone injected and dying ,not getting well

Confined · 56-60, M

@samueltyler2 the vax did nothing. It did not prevent any one from getting sick, it did not stop the spread, it did not prevent hospitalization. So why do we want people to take it? Fauci made billions. Most of the US politicians made billions. We know the people who made the vaxes made trillions.
Yet the vax killed 30 million people.

ElwoodBlues · M

Thanks for posting this more recent result that corroborates an earlier study:

A double-blind, randomized, placebo-controlled, adaptive platform trial involving 3515 symptomatic SARS-CoV-2–positive adults recruited from 12 public health clinics in Brazil.

Conclusions
Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19.

https://www.nejm.org/doi/full/10.1056/NEJMoa2115869

A big part of the process of science is independent checking of results. If a result isn't repeatable, it's questionable. repeatability is the hallmark of good science.

P.S. Alas, the tex chik and the brown stone have both blocked me and cannot see the confirming study posted here. I suspect they have an immunity to such facts as might contradict their preconceptions, so not too much is lost.